243 related articles for article (PubMed ID: 12915597)
1. Patterns of failure using a conformal radiation therapy tumor bed boost for medulloblastoma.
Wolden SL; Dunkel IJ; Souweidane MM; Happersett L; Khakoo Y; Schupak K; Lyden D; Leibel SA
J Clin Oncol; 2003 Aug; 21(16):3079-83. PubMed ID: 12915597
[TBL] [Abstract][Full Text] [Related]
2. Concurrent chemotherapy and reduced-dose cranial spinal irradiation followed by conformal posterior fossa tumor bed boost for average-risk medulloblastoma: efficacy and patterns of failure.
Douglas JG; Barker JL; Ellenbogen RG; Geyer JR
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1161-4. PubMed ID: 15001259
[TBL] [Abstract][Full Text] [Related]
3. Disease control and ototoxicity using intensity-modulated radiation therapy tumor-bed boost for medulloblastoma.
Polkinghorn WR; Dunkel IJ; Souweidane MM; Khakoo Y; Lyden DC; Gilheeney SW; Becher OJ; Budnick AS; Wolden SL
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e15-20. PubMed ID: 21481547
[TBL] [Abstract][Full Text] [Related]
4. Low-dose craniospinal irradiation and ifosfamide, cisplatin and etoposide for non-metastatic embryonal tumors in the central nervous system.
Yasuda K; Taguchi H; Sawamura Y; Ikeda J; Aoyama H; Fujieda K; Ishii N; Kashiwamura M; Iwasaki Y; Shirato H
Jpn J Clin Oncol; 2008 Jul; 38(7):486-92. PubMed ID: 18573848
[TBL] [Abstract][Full Text] [Related]
5. Conformal radiotherapy, reduced boost volume, hyperfractionated radiotherapy, and online quality control in standard-risk medulloblastoma without chemotherapy: results of the French M-SFOP 98 protocol.
Carrie C; Muracciole X; Gomez F; Habrand JL; Benhassel M; Mege M; Mahé M; Quetin P; Maire JP; Soum F; Baron MH; Clavere P; Chapet S; Gaci Z; Kolodie H; Maingon P; Vie B; Bernier V; Alapetite C; Hoffstetter S; Grill J; Lafay F;
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):711-6. PubMed ID: 15927408
[TBL] [Abstract][Full Text] [Related]
6. Longterm treatment results of childhood medulloblastoma by craniospinal irradiation in supine position.
Slampa P; Pavelka Z; Dusek L; Hynkova L; Sterba J; Ondrova B; Princ D; Novotny T; Kostakova S
Neoplasma; 2007; 54(1):62-7. PubMed ID: 17203894
[TBL] [Abstract][Full Text] [Related]
7. Online quality control, hyperfractionated radiotherapy alone and reduced boost volume for standard risk medulloblastoma: long-term results of MSFOP 98.
Carrie C; Grill J; Figarella-Branger D; Bernier V; Padovani L; Habrand JL; Benhassel M; Mege M; Mahé M; Quetin P; Maire JP; Baron MH; Clavere P; Chapet S; Maingon P; Alapetite C; Claude L; Laprie A; Dussart S
J Clin Oncol; 2009 Apr; 27(11):1879-83. PubMed ID: 19273707
[TBL] [Abstract][Full Text] [Related]
8. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.
Packer RJ; Gajjar A; Vezina G; Rorke-Adams L; Burger PC; Robertson PL; Bayer L; LaFond D; Donahue BR; Marymont MH; Muraszko K; Langston J; Sposto R
J Clin Oncol; 2006 Sep; 24(25):4202-8. PubMed ID: 16943538
[TBL] [Abstract][Full Text] [Related]
9. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience.
Kam MK; Teo PM; Chau RM; Cheung KY; Choi PH; Kwan WH; Leung SF; Zee B; Chan AT
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1440-50. PubMed ID: 15590175
[TBL] [Abstract][Full Text] [Related]
10. Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma.
Merchant TE; Kun LE; Krasin MJ; Wallace D; Chintagumpala MM; Woo SY; Ashley DM; Sexton M; Kellie SJ; Ahern V; Gajjar A
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):782-7. PubMed ID: 17892918
[TBL] [Abstract][Full Text] [Related]
11. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
[TBL] [Abstract][Full Text] [Related]
13. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma.
Mulhern RK; Palmer SL; Merchant TE; Wallace D; Kocak M; Brouwers P; Krull K; Chintagumpala M; Stargatt R; Ashley DM; Tyc VL; Kun L; Boyett J; Gajjar A
J Clin Oncol; 2005 Aug; 23(24):5511-9. PubMed ID: 16110011
[TBL] [Abstract][Full Text] [Related]
14. No salvage using high-dose chemotherapy plus/minus reirradiation for relapsing previously irradiated medulloblastoma.
Massimino M; Gandola L; Spreafico F; Biassoni V; Luksch R; Collini P; Solero CN; Simonetti F; Pignoli E; Cefalo G; Poggi G; Modena P; Mariani L; Potepan P; Podda M; Casanova M; Pecori E; Acerno S; Ferrari A; Terenziani M; Meazza C; Polastri D; Ravagnani F; Fossati-Bellani F
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1358-63. PubMed ID: 19019566
[TBL] [Abstract][Full Text] [Related]
15. Incidence, risks, and sequelae of posterior fossa syndrome in pediatric medulloblastoma.
Korah MP; Esiashvili N; Mazewski CM; Hudgins RJ; Tighiouart M; Janss AJ; Schwaibold FP; Crocker IR; Curran WJ; Marcus RB
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):106-12. PubMed ID: 19695790
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
Chen GY; Jiang GL; Wang LJ; Qian H; Fu XL; Yang H; Wu KL; Zhao S
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):70-5. PubMed ID: 15629596
[TBL] [Abstract][Full Text] [Related]
17. Radiation treatment for medulloblastoma: a review of 64 cases at a single institute.
Liu Y; Zhu Y; Gao L; Xu G; Yi J; Liu X; Li Y
Jpn J Clin Oncol; 2005 Mar; 35(3):111-5. PubMed ID: 15741299
[TBL] [Abstract][Full Text] [Related]
18. A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study.
Cho KH; Ahn SJ; Pyo HR; Kim KS; Kim YC; Moon SH; Han JY; Kim HT; Koom WS; Lee JS
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1397-404. PubMed ID: 19117690
[TBL] [Abstract][Full Text] [Related]
19. Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy.
Taylor RE; Bailey CC; Robinson KJ; Weston CL; Walker DA; Ellison D; Ironside J; Pizer BL; Lashford LS
Eur J Cancer; 2005 Mar; 41(5):727-34. PubMed ID: 15763649
[TBL] [Abstract][Full Text] [Related]
20. Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium.
Marks LB; Garst J; Socinski MA; Sibley G; Blackstock AW; Herndon JE; Zhou S; Shafman T; Tisch A; Clough R; Yu X; Turrisi A; Anscher M; Crawford J; Rosenman J;
J Clin Oncol; 2004 Nov; 22(21):4329-40. PubMed ID: 15514374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
